Original post:
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Related Post
- Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer - February 25th, 2025
- Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the... - February 25th, 2025
- Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 - February 25th, 2025
- Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference - February 25th, 2025
- BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt - February 25th, 2025
- atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - February 25th, 2025
- Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - February 25th, 2025
- Travere Therapeutics to Participate at Upcoming Investor Conferences - February 25th, 2025
- Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting - February 25th, 2025
- Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025 - February 25th, 2025
- Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma - February 25th, 2025
- Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine - February 25th, 2025
- argenx to Present at TD Cowen 45th Annual Healthcare Conference - February 25th, 2025
- PCI Biotech: Invitation to preliminary full-year 2024 results presentation - February 25th, 2025
- Opdateret finanskalender 2025 - February 25th, 2025
- CancerVax Announces Successful Tests of its Smart mRNA Technology - February 25th, 2025
- ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2... - February 25th, 2025
- Notice to the Annual General Meeting of Orion Corporation - February 25th, 2025
- Orion Group Financial Statement Release January–December 2024 - February 25th, 2025
- Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company’s key persons - February 25th, 2025
- Change to the Executive Leadership Team - February 23rd, 2025
- Nusano Named “Researcher of the Year” at Inaugural Best of BioHive Awards - February 23rd, 2025
- Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC - February 23rd, 2025
- Seer to Participate in the TD Cowen 45th Annual Health Care Conference - February 23rd, 2025
- Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - February 23rd, 2025
- NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - February 23rd, 2025
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial... - February 23rd, 2025
- Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million - February 23rd, 2025
- Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call - February 23rd, 2025
- Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - February 23rd, 2025
- Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - February 23rd, 2025
- Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel... - February 23rd, 2025
- Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration - February 23rd, 2025
- Dogecoin Cash, Inc. (OTC:CBDS) Announces Strategic Expansion of Crypto Holdings with Acquisition of 420 Million Dogecoin Cash ($DOG) - February 23rd, 2025
- Ipsen S.A. publishes its 2024 consolidated financial statements - February 23rd, 2025
- Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - February 23rd, 2025
- eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - February 23rd, 2025
- Fortrea to Add Erin L. Russell to Board of Directors - February 23rd, 2025
- Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative... - February 23rd, 2025
- Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease - February 23rd, 2025
- Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference - February 19th, 2025
- Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal - February 19th, 2025
- IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - February 19th, 2025
- Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 - February 19th, 2025
- eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering - February 19th, 2025
- Myriad Genetics Included in Forbes America’s Best Employers 2025 List - February 19th, 2025
- Annovis to Host Patients’ Live Forum on February 27, 2025 - February 19th, 2025
- Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - February 19th, 2025
- Kane Biotech Announces Second and Final Closing of Private Placement Offering - February 19th, 2025
- Kaida BioPharma Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - February 19th, 2025
- Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - February 19th, 2025
- GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - February 19th, 2025
- Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - February 19th, 2025
- Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - February 19th, 2025
- Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - February 19th, 2025
- Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - February 19th, 2025
- NAYA Biosciences Announces Nomination of New Board Members - February 19th, 2025
- Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology - February 19th, 2025
- OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors - February 19th, 2025
- Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers - February 19th, 2025
- Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares - February 17th, 2025
- Theratechnologies Resumes Distribution of EGRIFTA SV® - February 17th, 2025
- Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 - February 17th, 2025
- Press Release Biocartis NV: Biocartis announces new data on early CAR-T vector load assessment with Idylla™ presented at ASTCT: A Potential... - February 17th, 2025
- Nxera Pharma Proposes Changes to its Board of Directors - February 17th, 2025
- Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - February 17th, 2025
- Volta Medical Artificial Intelligence-guided Cardiac Ablation Procedure Improves Treatment of Atrial Fibrillation - February 17th, 2025
- Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain... - February 17th, 2025
- Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - February 17th, 2025
- Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) - February 17th, 2025
- Targeted Genomics Receives FDA Clearance for First Direct-to-Consumer Celiac Disease Genetic Health Risk Test - February 17th, 2025
- Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association... - February 15th, 2025
- CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK... - February 15th, 2025
- ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - February 15th, 2025
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - February 15th, 2025
- Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination - February 15th, 2025
- Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - February 15th, 2025
- Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - February 15th, 2025
- Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - February 15th, 2025
- Ensho Therapeutics Announces Upcoming Presentation at ECCO 2025 of Phase 1, Once-Daily Dosing Data for NSHO-101, an Oral α4β7 Inhibitor for... - February 15th, 2025
Recent Comments